Navigation Links
Shire Supports Rare Disease Day 2010

CAMBRIDGE, Massachusetts and BASINGSTOKE, England, March 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it will actively support Rare Disease Day across the world by generating media coverage in many countries to raise awareness and understanding of rare diseases.

Rare Disease Day seeks to call attention to rare diseases as a public health issue, and to reinforce the increased need for access to information, research and treatment. It is coordinated at the international level by European Organisation for Rare Diseases (EURORDIS) and by the National Organization for Rare Disorders (NORD) in the US.

It is estimated that there are between 5,000 and 8,000 known rare diseases affecting 250 million people in the world. Shire has commercially approved and available treatments for Fabry disease, Hereditary Angioedema (HAE) and Hunter syndrome. In addition, Shire expects the U.S. Food & Drug Administration (FDA) to issue its decision for VPRIVTM (velaglucerase alfa for injection), Shire's investigational enzyme replacement treatment for Type 1 Gaucher disease, by February 28.

"For many patients and their families, the journey to a diagnosis and subsequent treatment can be a long, complicated process," said Sylvie Gregoire, President of Shire Human Genetic Therapies (HGT). "Shire is committed to enabling people with life-altering conditions to lead better lives - and for us, this includes improving access to information as well as providing much-needed treatment for rare diseases."

    Shire's Global Rare Disease Day Initiatives include:

    - Extending (, its
    online resource center that aims to connect patients with each other and
    to provide important information about rare diseases.

    - Supporting the Global Genes Project (
    , a grassroots effort to use denim jeans to raise global awareness of
    rare genetic disorders.

    - Supporting its non-profit partners as they visit Capitol Hill to
    advocate for patients with rare diseases in Washington, D.C.,

    - Co-sponsoring with FEDER (Spanish Federation for Rare Diseases) the
    Annual Running Race for Rare Disease Day in Madrid, Spain.

    - Organizing a special walk on February 28th in Brazil to raise awareness
    of rare diseases in the country. It is expected that more than 20 patient
    organizations and their members will participate.

    For the full press release please visit
    Media Contact
    Jessica Mann (Rest of the World) +44(0)1256-894-280

    Jessica Cotrone (North America, HGT) +1-617-613-4640

SOURCE Shire Pharmaceutical

Back to top
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... 24, 2015 , ... In harsh industrial processes, the safety ... sensors can represent a weak spot where leaking process media is a possible ... housings , which are designed to tolerate extreme process conditions. They combine rugged ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):